Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen
Johan Rosell(Linköping University), John Carstensen(Linköping University), Olle Stål(Linköping University), Arne Wallgren(Sahlgrenska University Hospital), Henrik Lindman(Uppsala University), Tommy� Fornander(Karolinska University Hospital), Per-Olof Malmström(Skåne University Hospital), Bo Nordenskjöld(Linköping University), Nils‐Olof Bengtsson, Thomas Hatschek(Karolinska University Hospital)
Cited by 32
Related Papers
Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment
|PLoS ONE|2009|504
Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients
|British Journal of Cancer|2002|393
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial
|The Lancet|2000|343
Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [<sup>68</sup>Ga]ABY-025 Affibody PET/CT
|Theranostics|2015|269
First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the <sup>111</sup>In-ABY-025 Affibody Molecule
|Journal of Nuclear Medicine|2014|260